Zenas BioPharma (NASDAQ:ZBIO) Shares Gap Up Following Insider Buying Activity

Zenas BioPharma, Inc. (NASDAQ:ZBIO) shares gapped up before the market opened on Tuesday after an insider bought additional shares in the company. The stock had previously closed at $16.91, but opened at $17.92. Zenas BioPharma shares last traded at $17.1280, with a volume of 103,687 shares trading hands.

Specifically, CEO Leon O. Moulder, Jr. purchased 60,000 shares of the business’s stock in a transaction on Monday, May 18th. The stock was purchased at an average cost of $16.88 per share, with a total value of $1,012,800.00. Following the acquisition, the chief executive officer directly owned 96,928 shares in the company, valued at approximately $1,636,144.64. This trade represents a 162.48% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Analyst Upgrades and Downgrades

ZBIO has been the topic of several research analyst reports. Citigroup reaffirmed a “buy” rating on shares of Zenas BioPharma in a report on Thursday. Zacks Research upgraded Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Friday, March 27th. Wall Street Zen raised shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research note on Saturday. Finally, Guggenheim lifted their target price on shares of Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, March 16th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Zenas BioPharma presently has an average rating of “Moderate Buy” and an average target price of $44.29.

More Zenas BioPharma News

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: CEO Leon O. Moulder, Jr. bought 60,000 shares at $16.88 each, a purchase worth about $1.0 million, signaling insider confidence in Zenas BioPharma’s outlook. Article Title
• Positive Sentiment: Zenas BioPharma announced it will present Phase 3 INDIGO trial results for obexelimab in IgG4-related disease at the EULAR 2026 Congress, a near-term clinical catalyst that could draw investor attention. Article Title
• Neutral Sentiment: HC Wainwright maintained a Buy rating and $44 price target, but lowered earnings estimates across several periods, including Q2, Q3, Q4 2026 and FY2026-FY2030, reflecting a more cautious profit outlook.
• Negative Sentiment: The analyst’s lower EPS forecasts suggest Zenas BioPharma may face stronger-than-expected losses over the next several years, which likely pressured sentiment on the stock.

Zenas BioPharma Stock Performance

The company has a 50 day simple moving average of $21.04 and a 200-day simple moving average of $26.62. The company has a debt-to-equity ratio of 1.04, a current ratio of 11.94 and a quick ratio of 11.94. The stock has a market cap of $1.09 billion, a P/E ratio of -2.04 and a beta of -0.61.

Zenas BioPharma (NASDAQ:ZBIO) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($1.46) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.01. During the same period in the prior year, the business earned ($0.80) EPS. On average, equities analysts expect that Zenas BioPharma, Inc. will post -4.25 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Quarry LP raised its stake in shares of Zenas BioPharma by 34.5% during the third quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after acquiring an additional 291 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Zenas BioPharma in the 3rd quarter valued at $30,000. GF Fund Management CO. LTD. bought a new position in shares of Zenas BioPharma during the 4th quarter valued at $38,000. BNP Paribas Financial Markets grew its holdings in shares of Zenas BioPharma by 120.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock valued at $70,000 after purchasing an additional 1,716 shares during the last quarter. Finally, CWM LLC raised its position in Zenas BioPharma by 48.3% in the 4th quarter. CWM LLC now owns 2,178 shares of the company’s stock worth $79,000 after purchasing an additional 709 shares during the period.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.